Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.684
Xuebing Liu, Lei Chen, Shuying Ma
To speculate an autophagy gene, secretion associated Ras related guanosine triphosphatase 1B related signaling pathway for nasopharyngeal carcinoma based on both in vitro and in vivo experiments. 120 nasopharyngeal carcinoma biopsies (pathologically confirmed) were analyzed and the differentially expressed genes were explored. The internal molecular mechanism was further investigated using the human nasopharyngeal carcinoma cell lines, CNE1, HONE1 and C666-1. The cell proliferation capacity examination and the metabolic assays were performed in CNE1 cell line. The subcutaneous xenograft tumor mice model was also established. Secretion associated Ras related guanosine triphosphatase 1B demonstrated a remarkable decreased activity in nasopharyngeal carcinoma tissues compared with sibling paracancerous tissues. The key components in mammalian target of rapamycin complex 1 but not mammalian target of rapamycin complex 2 were greatly enhanced in nasopharyngeal carcinoma tissues. Moreover, the secretion associated Ras related guanosine triphosphatase 1B displayed a significant decreasing expression pattern and the mammalian target of rapamycin complex 1 kept an upward trend as the tumor, node and metastases stage progressed. The clinical significances for nasopharyngeal carcinoma tumor progression were calculated based on statistical analysis. The cell proliferation assay suggested that secretion associated Ras related guanosine triphosphatase 1B manipulated nasopharyngeal carcinoma cell proliferation via mammalian target of rapamycin complex 1/p70 ribosomal protein kinase 1 dependent signaling pathway. At the same time, transfection of secretion associated Ras related guanosine triphosphatase 1B small interfering ribonucleic acid could significantly enhanced the glycolytic capacity and glycolytic reserve of nasopharyngeal carcinoma cells compared with negative control. Silencing of secretion associated Ras related guanosine triphosphatase 1B promoted xenograft tumour growth, which could be greatly suppressed by rapamycin treatment in a dosage-dependent manner. The study shed a variety of insights for nasopharyngeal carcinoma from an innovative direction
{"title":"Role of SAR1B on Modulation of Nasopharyngeal Carcinoma Progression via Negative Regulation of Target of Rapamycin Complex 1 Signaling","authors":"Xuebing Liu, Lei Chen, Shuying Ma","doi":"10.36468/pharmaceutical-sciences.spl.684","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.684","url":null,"abstract":"To speculate an autophagy gene, secretion associated Ras related guanosine triphosphatase 1B related signaling pathway for nasopharyngeal carcinoma based on both in vitro and in vivo experiments. 120 nasopharyngeal carcinoma biopsies (pathologically confirmed) were analyzed and the differentially expressed genes were explored. The internal molecular mechanism was further investigated using the human nasopharyngeal carcinoma cell lines, CNE1, HONE1 and C666-1. The cell proliferation capacity examination and the metabolic assays were performed in CNE1 cell line. The subcutaneous xenograft tumor mice model was also established. Secretion associated Ras related guanosine triphosphatase 1B demonstrated a remarkable decreased activity in nasopharyngeal carcinoma tissues compared with sibling paracancerous tissues. The key components in mammalian target of rapamycin complex 1 but not mammalian target of rapamycin complex 2 were greatly enhanced in nasopharyngeal carcinoma tissues. Moreover, the secretion associated Ras related guanosine triphosphatase 1B displayed a significant decreasing expression pattern and the mammalian target of rapamycin complex 1 kept an upward trend as the tumor, node and metastases stage progressed. The clinical significances for nasopharyngeal carcinoma tumor progression were calculated based on statistical analysis. The cell proliferation assay suggested that secretion associated Ras related guanosine triphosphatase 1B manipulated nasopharyngeal carcinoma cell proliferation via mammalian target of rapamycin complex 1/p70 ribosomal protein kinase 1 dependent signaling pathway. At the same time, transfection of secretion associated Ras related guanosine triphosphatase 1B small interfering ribonucleic acid could significantly enhanced the glycolytic capacity and glycolytic reserve of nasopharyngeal carcinoma cells compared with negative control. Silencing of secretion associated Ras related guanosine triphosphatase 1B promoted xenograft tumour growth, which could be greatly suppressed by rapamycin treatment in a dosage-dependent manner. The study shed a variety of insights for nasopharyngeal carcinoma from an innovative direction","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.688
Qijian Huang, Shuangming Lin, Jundi Zhong
Huang
黄
{"title":"Effect of Huayu Qufu Shengji Decoction on Postoperative Pain and Wound Healing Time in Patients with Perianal Abscess","authors":"Qijian Huang, Shuangming Lin, Jundi Zhong","doi":"10.36468/pharmaceutical-sciences.spl.688","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.688","url":null,"abstract":"Huang","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.622
Z. Wang, Y. Zhong, Yan Dai, W. Wang, Wenli Su, Liuqing Wu, Mengwen Chen
{"title":"Application of PRECEDE-PROCEED Model in Health Education of Young and Middle-Aged with Lumbar Disc Herniation","authors":"Z. Wang, Y. Zhong, Yan Dai, W. Wang, Wenli Su, Liuqing Wu, Mengwen Chen","doi":"10.36468/pharmaceutical-sciences.spl.622","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.622","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69634330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.626
H. Tashkandi
{"title":"Therapeutic Potential of Pomegranate (Punica granatum Linn.) against Breast Cancer","authors":"H. Tashkandi","doi":"10.36468/pharmaceutical-sciences.spl.626","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.626","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69634380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.627
Z. Gao, C. Qian, Liang Zhang
{"title":"Role of Serum C-C Motif Chemokine Ligand 2 Monocyte Chemotactic Activities in Patients with Non Small Cell Lung Cancer","authors":"Z. Gao, C. Qian, Liang Zhang","doi":"10.36468/pharmaceutical-sciences.spl.627","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.627","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69634393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.666
Jiawen Lu, Y. Xiong, LI J.D.
:
：
{"title":"CCT2 Gene Expression in Hepatocellular Carcinoma and its Effect on the Biological Function of Hepatocellular Carcinoma Cells","authors":"Jiawen Lu, Y. Xiong, LI J.D.","doi":"10.36468/pharmaceutical-sciences.spl.666","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.666","url":null,"abstract":":","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"41 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69635064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1078
M. Harika, P. Radhika
{"title":"Antiproliferiative Activity of Biogenic Silver Nanoparticles Synthesized from Leonotis nepetifolia (L) on Human Cancer Cell lines","authors":"M. Harika, P. Radhika","doi":"10.36468/pharmaceutical-sciences.1078","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1078","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70215553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1075
Yuehui Juan, Yuehui Yu, L. Yi, L. Yang
To investigate the effect of pristimerin on gefitinib resistance in lung cancer cells and its regulation on microRNA-936. Lung cancer cell HCC827 was cultured in vitro , lung cancer gefitinib resistant cell HCC827/gefitinib resistant was established and HCC827/gefitinib resistant cells were randomly assigned to control group, pristimerin-L group, pristimerin-M group, pristimerin-H group, gefitinib group, gefitinib+pristimerin group, gefitinib+microRNA-negative control group, gefitinib+microRNA-936 group, gefitinib+pristimerin+anti-microRNA negative control group and gefitinib+pristimerin+anti-microRNA-936 group. 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide was used to detect the inhibition rate of cell proliferation, as well as the median half-maximal inhibitory concentration; the expression amount of microRNA-936 was detected by quantitative reverse transcription-polymerase chain reaction; cell migration and invasion were detected by transwell chamber assay. Compared with HCC827 cells, the proliferation inhibition rate of HCC827/gefitinib resistant cells was significantly lower and the half-maximal inhibitory concentration value was significantly higher (p<0.05); compared with the control group, the inhibition rate of cell proliferation was increased, the half-maximal inhibitory concentration value was decreased and the expression of microRNA-936 was increased (p<0.05) in pristimerin-L group, pristimerin-M group and pristimerin-H group; compared with the gefitinib group, the inhibition rate of cell proliferation was higher and the number of migration and invasion cells decreased in the gefitinib+pristimerin group (p<0.05); compared with the gefitinib+microRNA negative control group, the gefitinib+microRNA-936 group showed higher cell proliferation inhibition rate and lower cell number in migration and invasion (p<0.05); compared with the gefitinib+pristimerin+anti-microRNA negative control group, the cell proliferation inhibition rate decreased and the migration and invasion cell numbers increased in the gefitinib+pristimerin+anti-microRNA-936 group (p<0.05). Pristimerin may enhance cell gefitinib sensitivity by inhibiting proliferation, migration and invasion of gefitinib resistant cells in lung cancer by up regulating microRNA-936 expression.
{"title":"Pristimerin Contributes to Gefitinib Resistance in Lung Cancer Cells by regulating microRNA-936 expression","authors":"Yuehui Juan, Yuehui Yu, L. Yi, L. Yang","doi":"10.36468/pharmaceutical-sciences.1075","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1075","url":null,"abstract":"To investigate the effect of pristimerin on gefitinib resistance in lung cancer cells and its regulation on microRNA-936. Lung cancer cell HCC827 was cultured in vitro , lung cancer gefitinib resistant cell HCC827/gefitinib resistant was established and HCC827/gefitinib resistant cells were randomly assigned to control group, pristimerin-L group, pristimerin-M group, pristimerin-H group, gefitinib group, gefitinib+pristimerin group, gefitinib+microRNA-negative control group, gefitinib+microRNA-936 group, gefitinib+pristimerin+anti-microRNA negative control group and gefitinib+pristimerin+anti-microRNA-936 group. 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide was used to detect the inhibition rate of cell proliferation, as well as the median half-maximal inhibitory concentration; the expression amount of microRNA-936 was detected by quantitative reverse transcription-polymerase chain reaction; cell migration and invasion were detected by transwell chamber assay. Compared with HCC827 cells, the proliferation inhibition rate of HCC827/gefitinib resistant cells was significantly lower and the half-maximal inhibitory concentration value was significantly higher (p<0.05); compared with the control group, the inhibition rate of cell proliferation was increased, the half-maximal inhibitory concentration value was decreased and the expression of microRNA-936 was increased (p<0.05) in pristimerin-L group, pristimerin-M group and pristimerin-H group; compared with the gefitinib group, the inhibition rate of cell proliferation was higher and the number of migration and invasion cells decreased in the gefitinib+pristimerin group (p<0.05); compared with the gefitinib+microRNA negative control group, the gefitinib+microRNA-936 group showed higher cell proliferation inhibition rate and lower cell number in migration and invasion (p<0.05); compared with the gefitinib+pristimerin+anti-microRNA negative control group, the cell proliferation inhibition rate decreased and the migration and invasion cell numbers increased in the gefitinib+pristimerin+anti-microRNA-936 group (p<0.05). Pristimerin may enhance cell gefitinib sensitivity by inhibiting proliferation, migration and invasion of gefitinib resistant cells in lung cancer by up regulating microRNA-936 expression.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70215157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1167
B. Manisha, B. Aishwarya, B. Shekar, P. Mahesh, R. Adepu, A. R Sai Pawan
An open label prospective interventional study was conducted on asthma and chronic obstructive pulmonary disease patients to assess the influence of pharmacist provided education on inhaler usage technique and its impact on therapeutic outcomes in patients with Asthma and chronic obstructive pulmonary disease. The study was approved by the institutional ethics committee and conducted in the pulmonology department of Kamineni Institute of Medical Sciences, Narketpalli, Telangana. Written informed consent was obtained from the recruited study patients. A suitably designed data collection form was designed to capture disease and lab details i.e. forced expiratory volume in the 1st second. A newly constructed and validated knowledge, attitude and practices questionnaire was administered to assess the knowledge about the disease and its management. An inhaler checklist was applied to every patient to assess the inhaler usage technique and provided suitable guidance to use the inhaler effectively and assessed the impact of education on the patient's therapeutic outcomes. Among the 20 patients, 11 (55 %) were females and 9 (45 %) were males. The mean age of the study patients was 54±3 y. A significant improvement in knowledge, attitude and practices scores was observed in the post-counselling stage (p<0.001) and inhaler usage technique (p<0.001) among the patient after providing the counselling. Correct education about disease and inhaler usage techniques had shown an improvement in patient ̓s therapeutic outcomes.
{"title":"Influence of Pharmacist Counselling on Inhaler Usage Technique on Therapeutic Outcomes in Asthma and Chronic Obstructive Pulmonary Disease Patients","authors":"B. Manisha, B. Aishwarya, B. Shekar, P. Mahesh, R. Adepu, A. R Sai Pawan","doi":"10.36468/pharmaceutical-sciences.1167","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1167","url":null,"abstract":"An open label prospective interventional study was conducted on asthma and chronic obstructive pulmonary disease patients to assess the influence of pharmacist provided education on inhaler usage technique and its impact on therapeutic outcomes in patients with Asthma and chronic obstructive pulmonary disease. The study was approved by the institutional ethics committee and conducted in the pulmonology department of Kamineni Institute of Medical Sciences, Narketpalli, Telangana. Written informed consent was obtained from the recruited study patients. A suitably designed data collection form was designed to capture disease and lab details i.e. forced expiratory volume in the 1st second. A newly constructed and validated knowledge, attitude and practices questionnaire was administered to assess the knowledge about the disease and its management. An inhaler checklist was applied to every patient to assess the inhaler usage technique and provided suitable guidance to use the inhaler effectively and assessed the impact of education on the patient's therapeutic outcomes. Among the 20 patients, 11 (55 %) were females and 9 (45 %) were males. The mean age of the study patients was 54±3 y. A significant improvement in knowledge, attitude and practices scores was observed in the post-counselling stage (p<0.001) and inhaler usage technique (p<0.001) among the patient after providing the counselling. Correct education about disease and inhaler usage techniques had shown an improvement in patient ̓s therapeutic outcomes.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135360666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1174
He Huang, Lei Zhao, Lijun Huang, Xue Wang, Liping Sun
To investigate the influence of harpagide isolated from Scrophularia ningpoensis Hemsl. on human umbilical vascular endothelial cells damage induced by oxidized low-density lipoprotein and its possible mechanism. Human umbilical vascular endothelial cells were cultured in vitro. Different doses (20, 40, 80 μmol/l) of harpagide were applied to treat human umbilical vascular endothelial cells induced by oxidized low-density lipoprotein, human umbilical vascular endothelial cells overexpressing microRNA-140-5p were induced by oxidized low-density lipoprotein, and 80 μg/ml harpagide was applied to treat oxidized low-density lipoprotein induced human umbilical vascular endothelial cells with microRNA-140-5p downregulation. Enzyme-linked immunosorbent assay kits were used to detect malondialdehyde content as well as superoxide dismutase and glutathione peroxidase activities. Flow cytometry and Western blot were utilized to investigate cell apoptosis. Ribonucleic acid expression was analyzed by real-time quantitative reverse transcription polymerase chain reaction. Different doses of harpagide (20, 40, 80 μmol/l) reduced the malondialdehyde content and the rate of apoptosis in oxidized low-density lipoprotein-stimulated human umbilical vascular endothelial cells (p<0.05), while elevated superoxide dismutase as well as glutathione peroxidase activities (p<0.05). MicroRNA-140- 5p overexpression reduced the malondialdehyde content and apoptosis in oxidized low-density lipoproteinstimulated human umbilical vascular endothelial cells while elevated superoxide dismutase as well as glutathione peroxidase activities (p<0.05). Harpagide promoted microRNA-140-5p expression in human umbilical vascular endothelial cells after oxidized low-density lipoprotein stimulation (p<0.05). MicroRNA- 140-5p knockdown reversed the inhibitory effect of harpagide in human umbilical vascular endothelial cells (p<0.05). Harpagide up-regulates microRNA-140-5p to inhibit the oxidative stress and apoptosis of oxidized low-density lipoprotein-induced human umbilical vascular endothelial cells.
{"title":"Harpagide Increases microRNA-140-5p Expression to inhibit Oxidised Low-Density Lipoprotein-Caused Human Umbilical Vascular Endothelial Cell Damage","authors":"He Huang, Lei Zhao, Lijun Huang, Xue Wang, Liping Sun","doi":"10.36468/pharmaceutical-sciences.1174","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1174","url":null,"abstract":"To investigate the influence of harpagide isolated from Scrophularia ningpoensis Hemsl. on human umbilical vascular endothelial cells damage induced by oxidized low-density lipoprotein and its possible mechanism. Human umbilical vascular endothelial cells were cultured in vitro. Different doses (20, 40, 80 μmol/l) of harpagide were applied to treat human umbilical vascular endothelial cells induced by oxidized low-density lipoprotein, human umbilical vascular endothelial cells overexpressing microRNA-140-5p were induced by oxidized low-density lipoprotein, and 80 μg/ml harpagide was applied to treat oxidized low-density lipoprotein induced human umbilical vascular endothelial cells with microRNA-140-5p downregulation. Enzyme-linked immunosorbent assay kits were used to detect malondialdehyde content as well as superoxide dismutase and glutathione peroxidase activities. Flow cytometry and Western blot were utilized to investigate cell apoptosis. Ribonucleic acid expression was analyzed by real-time quantitative reverse transcription polymerase chain reaction. Different doses of harpagide (20, 40, 80 μmol/l) reduced the malondialdehyde content and the rate of apoptosis in oxidized low-density lipoprotein-stimulated human umbilical vascular endothelial cells (p<0.05), while elevated superoxide dismutase as well as glutathione peroxidase activities (p<0.05). MicroRNA-140- 5p overexpression reduced the malondialdehyde content and apoptosis in oxidized low-density lipoproteinstimulated human umbilical vascular endothelial cells while elevated superoxide dismutase as well as glutathione peroxidase activities (p<0.05). Harpagide promoted microRNA-140-5p expression in human umbilical vascular endothelial cells after oxidized low-density lipoprotein stimulation (p<0.05). MicroRNA- 140-5p knockdown reversed the inhibitory effect of harpagide in human umbilical vascular endothelial cells (p<0.05). Harpagide up-regulates microRNA-140-5p to inhibit the oxidative stress and apoptosis of oxidized low-density lipoprotein-induced human umbilical vascular endothelial cells.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"266 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135360667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：